Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has provided an update on the regulatory pathway for its CARA artificial intelligence platform, which is designed for early detection of eye-related health issues. The company confirmed progress across three targeted jurisdictions as part of its previously announced acceleration plan. This development is significant as it moves the platform closer to potential commercialization in key global markets, addressing a critical need for early diagnosis of conditions such as diabetic retinopathy and glaucoma.
According to the announcement, Diagnos has made a formal submission to the Saudi Food and Drug Authority (SFDA) for marketing approval. The company is also engaged with Health Canada, with a formal application expected this quarter. Additionally, it has clarified 510(k) requirements with the U.S. Food and Drug Administration (FDA), which streamlines the path for market entry in the United States. These regulatory steps are crucial for bringing CARA to healthcare providers and patients worldwide.
The CARA platform leverages artificial intelligence to analyze retinal images, assisting clinicians in detecting early signs of eye diseases. This technology has the potential to improve diagnostic accuracy, streamline workflows, and enhance patient outcomes, particularly in underserved areas where access to specialists is limited. The regulatory progress marks a milestone for Diagnos as it transitions from development to commercialization.
Diagnos is a publicly traded Canadian corporation focused on early detection of critical eye-related health problems. The company aims to provide more information to healthcare clinicians through AI-driven solutions. For more details on the regulatory update, the full press release is available at https://ibn.fm/uUewJ.
Additional information about Diagnos can be found on its website at www.diagnos.com and on SEDAR+ at www.sedarplus.com. Investors can stay updated on the latest news and developments regarding DGNOF in the company’s newsroom at https://ibn.fm/DGNOF.
